NDAINJECTIONINJECTABLE
Approved
May 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Selenomethionine SE-75 is a radioactive diagnostic injectable approved in 1973 for imaging applications. This radiopharmaceutical is a selenium-75 labeled amino acid used primarily for pancreatic and other organ imaging. The drug functions as a diagnostic tracer, accumulating in target tissues to enable visualization via nuclear imaging.
LOE Approaching
With LOE approaching and minimal linked job activity, this legacy diagnostic faces commercial contraction and reduced team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the legacy status and declining commercial relevance of this 1973-approved radiopharmaceutical. Professionals assigned to this product face limited growth opportunity and should anticipate redeployment or portfolio rationalization.
Medical Affairs SpecialistRegulatory Affairs Analyst
Worked on SELENOMETHIONINE SE 75 at PharmaLundensis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.